| Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells MA Molina, J Codony-Servat, J Albanell, F Rojo, J Arribas, J Baselga Cancer research 61 (12), 4744-4749, 2001 | 1072 | 2001 |
| Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer M Scaltriti, F Rojo, A Ocaña, J Anido, M Guzman, J Cortes, S Di Cosimo, ... Journal of the National Cancer Institute 99 (8), 628-638, 2007 | 1045 | 2007 |
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations V Serra, B Markman, M Scaltriti, PJA Eichhorn, V Valero, M Guzman, ... Cancer research 68 (19), 8022-8030, 2008 | 925 | 2008 |
| Interrogating open issues in cancer precision medicine with patient-derived xenografts AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ... Nature Reviews Cancer 17 (4), 254-268, 2017 | 660 | 2017 |
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ... Oncogene 30 (22), 2547-2557, 2011 | 608 | 2011 |
| Diverse Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors (∗) J Arribas, L Coodly, P Vollmer, TK Kishimoto, S Rose-John, J Massagué Journal of Biological Chemistry 271 (19), 11376-11382, 1996 | 530 | 1996 |
| Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity M Scaltriti, C Verma, M Guzman, J Jimenez, JL Parra, K Pedersen, ... Oncogene 28 (6), 803-814, 2009 | 495 | 2009 |
| Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity M Roghani, JD Becherer, ML Moss, RE Atherton, H Erdjument-Bromage, ... Journal of Biological Chemistry 274 (6), 3531-3540, 1999 | 417 | 1999 |
| Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225) superiority over … P Matar, F Rojo, R Cassia, G Moreno-Bueno, S Di Cosimo, J Tabernero, ... Clinical cancer research 10 (19), 6487-6501, 2004 | 368 | 2004 |
| TACE is required for the activation of the EGFR by TGF‐α in tumors M Borrell‐Pagès, F Rojo, J Albanell, J Baselga, J Arribas The EMBO journal, 2003 | 360 | 2003 |
| Mechanism of action of trastuzumab and scientific update J Baselga, J Albanell, MA Molina, J Arribas Seminars in oncology 28, 4-11, 2001 | 360 | 2001 |
| RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, ... Annals of Oncology 29 (5), 1203-1210, 2018 | 346 | 2018 |
| Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells J Codony-Servat, J Albanell, JC Lopez-Talavera, J Arribas, J Baselga Cancer research 59 (6), 1196-1201, 1999 | 340 | 1999 |
| ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents … J Anido, P Matar, J Albanell, M Guzmán, F Rojo, J Arribas, S Averbuch, ... Clinical Cancer Research 9 (4), 1274-1283, 2003 | 299 | 2003 |
| Protein ectodomain shedding J Arribas, A Borroto Chemical reviews 102 (12), 4627-4638, 2002 | 298 | 2002 |
| Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors G Velasco, S Cal, A Merlos-Suárez, AA Ferrando, S Alvarez, A Nakano, ... Cancer Research 60 (4), 877-882, 2000 | 290 | 2000 |
| Identification and characterization of Cardiac Glycosides as senolytic compounds F Triana-Martínez, P Picallos-Rabina, S Da Silva-Álvarez, F Pietrocola, ... Nature communications 10 (1), 4731, 2019 | 281 | 2019 |
| p95HER2 and breast cancer J Arribas, J Baselga, K Pedersen, JL Parra-Palau Cancer research 71 (5), 1515-1519, 2011 | 276 | 2011 |
| Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translation J Anido, M Scaltriti, JJ Bech Serra, BS Josefat, F Rojo Todo, J Baselga, ... The EMBO journal 25 (13), 3234-3244, 2006 | 275 | 2006 |
| A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis K Pedersen, PD Angelini, S Laos, A Bach-Faig, MP Cunningham, ... Molecular and cellular biology 29 (12), 3319-3331, 2009 | 219 | 2009 |
